Cognitive Research Corporation Names Jason Casarella as New Chief Commercial Officer

CRC Appoints Jason Casarella as Chief Commercial Officer

Cognitive Research Corporation (CRC) has announced the significant appointment of Jason Casarella, MBA, as its new Chief Commercial Officer, effective immediately. This move is aimed at further solidifying CRC’s position as a leading full-service contract research organization (CRO) specializing in clinical trials for central nervous system (CNS) disorders.

An Experienced Leader Joins the Team

Mr. Casarella brings over 28 years of extensive experience in the CRO industry, having worked in numerous senior management roles where he has developed a keen insight into business development, marketing, and commercial strategy. His career began as a Clinical Research Associate, where he quickly made a name for himself through his hard work and dedication, subsequently rising through the ranks to assume pivotal leadership roles in various respected organizations.

“Jason's proven experience leading high-performing teams and forging strategic partnerships will be instrumental as CRC continues to advance our work with sponsors to bring new CNS therapies closer to market,” said Tom Zoda, Ph.D., CEO of CRC. This statement underscores the high expectations CRC has for their new CCO, who is expected to facilitate growth through strong partnerships and innovative strategies.

Proven Track Record in the CRO Sector

Before joining CRC, Mr. Casarella notably spent over a decade at Advanced Clinical, where he played a crucial role in transforming the company from a niche, U.S.-focused organization into a competitive global midsize CRO. His previous engagements included pivotal roles at Covance, PharmaNet, and PRA Health Sciences, further enriching his expertise and understanding of the complexities of clinical trials.

In 2019, his industry leadership was recognized when he was named among PharmaVoice's 100 Most Inspiring People, highlighting his commitment to excellence and innovation within the CRO space.

Commitment to CNS Research

Expressing his enthusiasm for his new role, Casarella stated, “I am honored to join CRC at such an important time in the company’s growth. Sponsors developing therapies for CNS disorders need a partner they can trust to deliver with expertise and consistency.” His passion for CNS research aligns with CRC’s mission and solidifies the company's commitment to improving patient outcomes through rigorous clinical testing.

With Casarella's appointment, CRC is poised to enter its next chapter with optimism and ambition, aiming to become the partner of choice in CNS clinical research. The integration of his strategic leadership is anticipated to yield results that not only enhance CRC's operational framework but also benefit countless individuals seeking new therapeutic options for CNS disorders.

About Cognitive Research Corporation

Cognitive Research Corporation is at the forefront of clinical research organizations, specializing exclusively in CNS disorders including areas like neurology, psychiatry, and analgesia. The company's approach to clinical trials combines innovative technology, comprehensive scientific expertise, and personalized support to deliver high-quality and efficient trials across different phases. With a focus on consistency, urgency, and accuracy, CRC is dedicated to bringing new therapies from initial testing to FDA approval, thereby enhancing the quality of life for patients worldwide.

For more information about CRC and its offerings, please visit www.cogres.com.